1. Treatment Outcomes in Patients with Conjunctival Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
- Author
-
Matsuo Y, Monden Y, Sasaki K, Akune H, Ikeda S, Ishio D, Murotani K, Nagafuji K, and Yoshida S
- Subjects
conjunctival mucosa-associated lymphoid tissue lymphoma ,overall survival ,relapse-free survival ,Ophthalmology ,RE1-994 - Abstract
Yu Matsuo,1 Yu Monden,1 Kensuke Sasaki,1 Hodaka Akune,1 Shuntaro Ikeda,1 Daiki Ishio,1 Kenta Murotani,2 Koji Nagafuji,3 Shigeo Yoshida1 1Department of Ophthalmology, Kurume University School of Medicine, Kurume, Japan; 2Biostatistics Center, Kurume University, Kurume, Japan; 3Department of Hematology and Oncology, Kurume University School of Medicine, Kurume, JapanCorrespondence: Yu Matsuo, Department of Ophthalmology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan, Tel +81 942 31 7574 ; Fax +81 942 37 0324, Email matsuo_yuu@med.kurume-u.ac.jpPurpose: To report the outcomes of different therapies in patients with conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma.Patients and Methods: This retrospective study included patients diagnosed with conjunctival MALT lymphoma between August 2000 and April 2022. Patients were classified into three groups according to their treatment: an observation group, a radiation therapy (RT) group, and a rituximab group (rituximab with or without chemotherapy). We analyzed overall survival (OS), overall, local, and systemic relapse-free survival (RFS), and adverse events after treatment.Results: This study included 15 patients (22 eyes). The 10-year OS was 100%. The 2-, 5-, and 10-year overall RFS rates were 80.1%, 41.2%, and 41.2% in all patients, respectively. The 2- and 5-year local RFS rates in the observation group were 100% and 0%, respectively. The 2-, 5-, and 10-year local RFS rates were 87%, 87%, and 87% in the RT group and 83%, 67%, and 67% in the rituximab group, respectively. The 2- and 5-year systemic RFS rates in the observation group were both 100%, and the 2-, 5-, and 10-year systemic RFS rates were 92%, 55%, and 55% in the RT group, and 100%, 60%, and 60% in the rituximab group, respectively. After RT, 53.3% of the eyes developed cataracts and 75% of these were treated with cataract surgery. In addition, 53.3% of the eyes developed dry eyes and were treated with eye drops. Rituximab with or without chemotherapy resulted in some systemic adverse events, but these improved following symptomatic therapies.Conclusion: RT resulted in good local control of conjunctival MALT lymphoma; however, systemic relapse may occur during long-term follow-up. Local and/or systemic relapse may also occur during long-term follow-up in patients treated by observation or rituximab with or without chemotherapy. Patients with conjunctival MALT lymphoma should be followed-up carefully for as long as possible after treatment.Keywords: conjunctival mucosa-associated lymphoid tissue lymphoma, overall survival, relapse-free survival
- Published
- 2024